Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (3450)	12/11/1997 9:29:00 PM
From: EyeDrMike	Read Replies (1) \| Respond to of 23519

Correction: .it was the plant in IRELAND they expected the approval on by the 2nd quarter and stated twice that in the USA it will be the 1st quarter. Mike

To: Linda Kaplan who wrote (3450)	12/12/1997 2:01:00 AM
From: Bruce Rosen	Read Replies (1) \| Respond to of 23519

<<When you spoke to Dr. Greco, did you happen to ask him why he chose not to use sexual intercourse as a criteria for efficacy and instead chose weight-lifting? Linda>> Hi Linda. I think the reason was that they couldn't find any women willing to have intercourse with a man who had a 1 kg weight hanging from his penis. I had heard that Italian women were wild and fun-loving, but this was apparently too much even for them. I am long Zona and have been reading the Vivus boards of late. Most of those who post negative comments on the Zona board come from here. Even now, with so much to concern Vivus longs, a few still take passing swipes at Zonagen. Yet, with the ridiculous Asensio comments on Vivus coming on the heels of his even more vicious and deceitful attack on Zonagen, we seem to have much in common, including an interest in growing the ED market as a whole. Joe Podolski of Zonagen has consistently expressed the view that the ED market will have room for many different treatments. Those that can't be helped by a pill will, in all likelihood, try Muse and if successful, will use it again. I think that both Vivus and Zonagen are excellent risk/reward plays right now and those who can persist through this difficult period, will be well rewarded. Good luck!